Dataset Information

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.

ABSTRACT: While the discovery of immune checkpoint inhibitors has led to robust, durable responses in a range of cancers, many patients do not respond to currently available therapeutics. Therefore, an urgent need exists to identify alternative mechanisms to augment the immune-mediated clearance of tumors. Hematopoetic progenitor kinase 1 (HPK1) is a serine-threonine kinase that acts as a negative regulator of T-cell receptor (TCR) signaling, to dampen the immune response. Herein we describe the structure-based discovery of isofuranones as inhibitors of HPK1. Optimization of the chemotype led to improvements in potency, selectivity, plasma protein binding, and metabolic stability, culminating in the identification of compound 24. Oral administration of 24, in combination with an anti-PD1 antibody, demonstrated robust enhancement of anti-PD1 efficacy in a syngeneic tumor model of colorectal cancer.

SUBMITTER: Degnan AP

PROVIDER: S-EPMC7957935 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.

Degnan Andrew P AP Kumi Godwin K GK Allard Christopher W CW Araujo Erika V EV Johnson Walter L WL Zimmermann Kurt K Pearce Bradley C BC Sheriff Steven S Futran Alan A Li Xin X Locke Gregory A GA You Dan D Morrison John J Parrish Karen E KE Stromko Caitlyn C Murtaza Anwar A Liu Jinqi J Johnson Benjamin M BM Vite Gregory D GD Wittman Mark D MD

ACS medicinal chemistry letters 20210219 3

While the discovery of immune checkpoint inhibitors has led to robust, durable responses in a range of cancers, many patients do not respond to currently available therapeutics. Therefore, an urgent need exists to identify alternative mechanisms to augment the immune-mediated clearance of tumors. Hematopoetic progenitor kinase 1 (HPK1) is a serine-threonine kinase that acts as a negative regulator of T-cell receptor (TCR) signaling, to dampen the immune response. Herein we describe the structure ...[more]

PMID: 33732413

Dataset Information

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.

Publications

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
| S-EPMC4025827 | biostudies-literature

Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.
| S-EPMC4017972 | biostudies-other

Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
| S-EPMC9290007 | biostudies-literature

Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.
| S-EPMC4948009 | biostudies-literature

Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.
| S-EPMC8201761 | biostudies-literature

Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR.
| S-EPMC5846042 | biostudies-literature

Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor.
| S-EPMC6900553 | biostudies-literature

Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.
| S-EPMC6580535 | biostudies-literature

Novel Potent Selective Orally Active S1P5 Receptor Antagonists.
| S-EPMC7957944 | biostudies-literature

Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.
| S-EPMC4753552 | biostudies-literature